Click here to read the full study

Click here to read a Q&A on the study

Click here to read the Executive summary

The Medicines Patent Pool (MPP) conducted a feasibility study to assess the public health need for – and the feasibility and potential public health impact of –  expanding its mandate from HIV, tuberculosis and hepatitis C to patented essential medicines in other therapeutic areas.

The Swiss Agency for Development and Cooperation funded the assessment after several stakeholders, including the World Health Organization (WHO) and the Lancet Commission on Essential Medicines Policies, recommended expansion of the MPP’s patent pooling model to all patented essential medicines, such as those included on the WHO Model List of Essential Medicines.

Expansion of the MPP’s mandate was also an integral part of recommendations on access to medicines and intellectual property discussed this year at the 71st World Health Assembly (documents A71/12 and A71/13).

Click below to read individual chapters:

Chapter 3 – Patented medicines included in the EML: Case study on medicines for chronic myeloid leukaemia

Chapter 4 – Patented medicines that the WHO Expert Committee considered as having relevant clinical benefits but needing additional data: Case study on novel medicines for type 2 diabetes

Chapter 5 – Patented medicines that have clinical benefits but did not meet the EML Expert Review committee’s comparative cost-effectiveness criterion: Case study on novel oral anticoagulants

Chapter 6 – Patented medicines for which the WHO Expert Committee recommended a therapeutic area review by a separate working group: Case studies on lung cancer, prostate cancer, multiple myeloma and breast cancer

Chapter 7 – New antibiotics to combat antimicrobial resistance

Chapter 8Other products in the WHO EML, highlighted by EML Committee or mentioned in discussions with stakeholders